Evidence map›Paper›PMID 41408349›Full record

ArticleGenome medicine2025

Genetic liability to psoriasis predicts severe disease outcomes.

Jake R Saklatvala, Samuel Lessard, Maris Teder-Laving, Laurent F Thomas, Ravi Ramessur, Jonas Zierer, Bjørn Olav Åsvold, Anne Barton, David Baudry, John Bowes and 43 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors.

Jake R SaklatvalaDepartment of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, SE1 9RT, UK.
Samuel Lessard *Target, Disease & Systems Biology, Sanofi Research, Cambridge, MA, USA.
Maris Teder-Laving *Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.
Laurent F Thomas *Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Ravi RamessurSt John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Jonas ZiererImmunology Disease Area, Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Bjørn Olav ÅsvoldHUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Anne BartonCentre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK.
David BaudrySt John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
John BowesCentre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK.
Ben BrumptonHUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Sandro BrunoImmunology Disease Area, Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Vinod ChandranSchroeder Arthritis Institute, Krembil Research Institute, and Toronto Western Hospital, University Health Network and Departments of Medicine/Rheumatology, Institute of Medical Science, and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Clément ChatelainTarget, Disease & Systems Biology, Sanofi Research, Cambridge, MA, USA.
Emanuele de RinaldisTarget, Disease & Systems Biology, Sanofi Research, Cambridge, MA, USA.
James T ElderDepartment of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA.
David EllinghausInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
John FoersterCollege of Medicine, Dentistry, and Nursing, University of Dundee, Dundee, UK.
Andre FrankeInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Dafna D GladmanSchroeder Arthritis Institute, Krembil Research Institute, and Toronto Western Hospital, University Health Network and Departments of Medicine/Rheumatology, Institute of Medical Science, and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Wayne GulliverNewlab Clinical Research Inc, St. John's, NL, Canada.
Ulrike HüffmeierInstitute of Human Genetics, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.
Laura HuilajaDepartment of Dermatology and Medical Research Center, Oulu University Hospital and Research Unit of Clinical Medicine, University of Oulu, Oulu, Finland.
Kristian HveemHUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Shameer KhaderTarget, Disease & Systems Biology, Sanofi Research, Cambridge, MA, USA.
Külli KingoFaculty of Medicine, Institute of Clinical Medicine, University of Tartu, Tartu University Hospital, Tartu, Estonia.
Katherine KlingerGenetics Research, Sanofi, Cambridge, MA, USA.
Frank KolbingerImmunology Disease Area, Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Sulev KõksPerron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia.
Wilson LiaoDeparment of Dermatology, University of California San Francisco, San Francisco, CA, USA.
Rajan P NairDepartment of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA.
Joanne NitithamDeparment of Dermatology, University of California San Francisco, San Francisco, CA, USA.
Proton RahmanMemorial University of Newfoundland, St. John's, NL, Canada.
André ReisInstitute of Human Genetics, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.
Manpreet K SagooSt John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Philip E StuartDepartment of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA.
Kaisa TasanenDepartment of Dermatology and Medical Research Center, Oulu University Hospital and Research Unit of Clinical Medicine, University of Oulu, Oulu, Finland.
Tanel TraksDepartment of Dermatology and Venereology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Lam C TsoiDepartment of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA.
Steffen UebeInstitute of Human Genetics, Universitätsklinikum Erlangen, FAU Erlangen-Nürnberg, Erlangen, Germany.
Katie WattsMRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK.
BSTOP study group
Jonathan N BarkerSt John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Satveer K MahilSt John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Sinéad M LanganFaculty of Epidemiology and Population Health, London, School of Hygiene and Tropical Medicine , London, UK.
FinnGen
Estonian Biobank research team
Sara J BrownCentre for Genomic & Experimental Medicine, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
Mari LøsetHUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Lavinia PaternosterMRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK.
Nick Dand *Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, SE1 9RT, UK.
Catherine H Smith *St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Michael A SimpsonDepartment of Medical & Molecular Genetics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, SE1 9RT, UK. michael.simpson@kcl.ac.uk.

Funding

Estonian Research Council PRG1911 and TK (TK214)Innovative Medicines Initiative 2 Joint Undertaking 821511NIHR Advanced Fellowship NIHR302258UK Medical Research Council Integrative Epidemiology Unit MC_UU_00011/1, MC_UU_00032/01Wellcome TrustWellcome Trust 220875/Z/20/Z
6 · The paper itself

Abstract

backgroundPsoriasis is a common inflammatory skin disease with heterogeneous presentation. Up to 30% of individuals have severe disease with a greater surface area of skin involvement, co-morbidity burden and impact on quality of life. Prognostic biomarkers of psoriasis severity could improve allocation of clinical resources and enable earlier intervention to prevent disease progression, and a genetic biomarker would be cost-effective, stable over time, and unaffected by treatment or comorbidity.

methodsPsoriasis severity was studied in four European population-based biobanks (Estonian Biobank, HUNT, FinnGen, UK Biobank) and classified based on level of clinical intervention received, with criteria for severe disease including hospitalisation due to psoriasis, use of systemic immunomodulating therapy or phototherapy. Common genetic variants, polygenic risk scores and traditional epidemiological risk factors were tested for association with severe psoriasis in each of the constituent biobanks and combined through meta-analysis. The distribution of psoriasis polygenic risk was also evaluated in a cohort of 4151 participants in the UK-based severe psoriasis registry, BSTOP, and a cohort of 1461 participants from Novartis clinical trials of secukinumab for psoriasis.

resultsIn the population-based datasets, 9738 of 44,904 individuals with psoriasis (21.7%) were classified as having severe disease. Genetic variants within the major histocompatibility complex (MHC) and the TNIP1 and IL12B psoriasis susceptibility loci were associated with severe disease at genome-wide significance (P < 5.0 × 10

conclusionsThe psoriasis susceptibility PRS demonstrates utility and may be more effective than established epidemiological factors, as a stratification tool to identify those individuals that are at greatest risk of severe disease and may benefit most from early intervention.

Indexed as

Genetic Predisposition to DiseasePsoriasisAdultAgedFemaleHumansMaleMiddle AgedMultifactorial InheritancePolymorphism, Single NucleotidePrognosisRisk FactorsSeverity of Illness IndexBiomarkerDermatologyDisease progressionGeneticsGenome-wide association studyImmune-mediated inflammatory diseasePolygenic risk scoreSeveritySkin disease

Identifiers

PMID41408349
PMCPMC12857016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.